High-density lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells

      This paper is only available as a PDF. To read, Please Download here.


      High concentrations of high-density lipoprotein (HDL) are known to decrease the risk of coronary artery disease. In order to study the underlying cellular mechanisms, the influence of HDL on the epidermal growth factor (EGF)-induced vascular smooth muscle cell (VSMC) proliferation was investigated. Approximately 40% of the EGF-induced increase of the cell DNA synthesis was abolished in the presence of 30 μg/ml HDL. The EGF-induced dose-dependent (10 pg/ml to 100 ng/ml) increase in DNA synthesis was blunted by 30 μg/ml HDL. In addition HDL (3–300 μg/ml caused a dose-dependent inhibition of EGF (20 ng/ml) -induced DNA synthesis, yielding a half maximal effective dose (ED50) of 30 μg/ml Similar experiments with the HDL-protein and HDL-lipid fraction indicated that the HDL-protein fraction is most probably responsible for the observed inhibiting effects of HDL. This was confirmed by using purified apolipoprotein (apo) A-I and apo A-II. Both induced an approximately 80% inhibition of the EGF-induced DNA synthesis. These results may help to explain the observed beneficial effects of HDL on cardiovascular diseases that are described in many epidemiological studies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gordon D.J.
        • Probstfield J.L.
        • Garrison R.J.
        • Neaton J.D.
        • Castelli W.P.
        • Knocke J.D.
        • Jacobs D.R.
        • Bangdiwala S.
        • Tyroler H.A.
        High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
        Circulation. 1989; 79: 8
        • Gordon D.J.
        • Rifkind B.M.
        High-density lipoprotein: the clinical implications of recent studies.
        N. Engl. J. Med. 1989; 321: 1311
        • Lechleitner M.
        • Miesenböck G.
        • Patsch J.R.
        HDL cholesterol, triglycerides and coronary heart disease.
        Curr. Opin. Lipidol. 1990; 1: 330
        • Stampfer M.J.
        • Sacks F.M.
        • Salvani S.
        • Willet W.C.
        • Hennekens C.H.
        A prospective study of cholesterol apolipoproteins, and the risk of myocardial infarction.
        N. Engl. J. Med. 1991; 325: 373
        • Fielding C.J.
        Reverse cholesterol transport.
        Curr. Opin. Lipidol. 1991; 2: 376
        • Ross R.
        The pathogenesis of atherosclerosis.
        N. Engl. J. Med. 1986; 314: 488
        • Risau W.
        • Zerwes H.G.
        Role of growth factor in the formation of blood vessels.
        Z. Kardiol. 1989; 78: 9
        • Schwartz S.M.
        • Campbell G.R.
        • Campbell J.H.
        Replication of smooth muscle cells in vascular disease.
        Circ. Res. 1986; 58: 427
        • Ross R.J.
        The smooth muscle cell II. Growth of smooth muscle in culture and formation of elastic fiber.
        J. Cell. Biol. 1971; 50: 172
        • Nemecek G.M.
        • Coughlin S.R.
        • Handley D.H.
        • Moskowitz M.
        Stimulation of aortic smooth muscle cell mitogenesis by serotonin.
        in: Proc. Natl. Acad. Sci. USA. 83. 1986: 674
        • Bradford M.
        A rapid and sensitive method of the quantitation of microgram quantities of protein utilizing the principal of protein-dye binding.
        Anal. Biochem. 1976; 72: 248
        • Redgrave T.G.
        • Robert D.C.K.
        • West C.E.
        Separation of plasma lipoproteins by density-gradient ultracentrifugation.
        Anal. Biochem. 1975; 65: 42
        • Wieland H.
        • Seidel D.
        Advances in the analysis of plasmalipoproteins.
        Innere Med. 1978; 7: 290
        • Wallenstein S.
        • Zucker C.L.
        • Fleiss J.L.
        Some statistical methods useful in circulation research.
        Circ. Res. 1980; 47: 1
        • Kukita H.
        • Hiwada K.
        • Kokubu T.
        Serum apoliprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease.
        Atherosclerosis. 1984; 51: 261
        • Miller N.E.
        • Hammet F.
        • Saltissi S.
        • van Zeller H.
        • Coltart J.
        • Lewis B.
        Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apoliproteins.
        Br. Med. J. 1981; 282: 1741
        • Rubin E.M.
        • Krauss R.M.
        • Spangle E.A.
        • Verstuyvt J.G.
        • Clift S.M.
        Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.
        Nature. 1991; 353: 265
        • Badimon J.J.
        • Badimon L.
        • Fuster V.
        Regression of atherosclerotic lesion by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.
        J. Clin. Invest. 1990; 85: 1234